Livzon Pharma advances share repurchase, cancels stock options

Livzon Pharmaceutical Group (SZSE:000513) is progressing with its previously announced share repurchase program, alongside the cancellation of specific stock options granted under its 2022 equity incentive plan. As of April 30, 2025, the company has repurchased 11,318,855 A shares, representing 1.24% of its total share capital, at prices ranging from CNY33.21 to CNY38.37 per share, for a total expenditure of CNY406,838,989.15 (excluding transaction fees). Simultaneously, Livzon has repurchased 7,245,300 H shares, accounting for 0.80% of the total share capital, at prices between HKD23.75 and HKD27.80 per share, utilizing HKD190,692,395.00 (excluding transaction fees).